Cargando…
Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy
Cardiac amyloidosis is a rare, debilitating, and usually fatal disease increasingly recognized in clinical practice despite patients presenting with non-specific symptoms of cardiomyopathy. The current standard of care (SoC) focuses on preventing further amyloid formation and deposition, either with...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808970/ https://www.ncbi.nlm.nih.gov/pubmed/36606280 http://dx.doi.org/10.3389/fcvm.2022.1073503 |